Theratechnologies Inc.

Stock Chart, Company Information, and Scan Results

$3.16(as of Jul 24, 3:58 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Theratechnologies Inc. Company Information, Fundamentals, and Technical Indicators

Stock Price$3.16
Ticker SymbolTHTX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
EmployeesUnknown
CountyUSA
Market Cap$145.1M
EBIDTA8.7M
10-Day Moving Average3.15
P/E Ratio-16.98
20-Day Moving Average2.95
Forward P/E Ratio55.87
50-Day Moving Average2.72
Earnings per Share-0.19
200-Day Moving Average1.94
Profit Margin-25.17%
RSI72.18
Shares Outstanding46.0M
ATR0.07
52-Week High3.20
Volume245,079
52-Week Low1.12
Most Recent Support Level2.28
Book Value-27.9M
Most Recent Resistance Level3.20
P/B Ratio-5.57
Upper Keltner3.10
P/S Ratio1.84
Lower Keltner2.80
Debt-to-Equity Ratio3.10
Next Earnings DateUnknown
Cash Surplus-29.7M
Next Ex-Dividend DateUnknown

Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin F8 in HIV-associated lipodystrophy that is in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; SORT1+ Technology that is in Phase 1 clinical trials for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; sudocetaxel zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company also commercializes olezarsen, an RNA-targeted medicine for the treatment of familial chylomicronemia syndrome and severe hypertriglyceridemia; and donidalorsen, an RNA-targeted medicine that targets the acute attacks of hereditary angioedema. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.